Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Zealand Pharma's 'More Commercial' CEO Jensen On Lixisenatide And Beyond

This article was originally published in Scrip

Executive Summary

Danish company Zealand Pharma, most noteworthy for developing the thus far commercially disappointing Sanofi-partnered GLP-1 receptor agonist Lyxumia (lixisenatide), appointed its new CEO a year ago, claiming it needed someone with a more commercial focus. Scrip caught up with Britt Meelby Jensen to find out what lessons the company has learned from the Lyxumia episode and how Zealand Pharma is moving beyond diabetes.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC063933

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel